Mitochondrial activity in the mapping of functional brain changes in schizophrenia

Restorative Neurology and Neuroscience

Volumn 12, Issue 2-3, 1998, Pages 185-193

  Prince, Jonathan A ^a   Oreland, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C OXIDASE; METHAMPHETAMINE; NEUROLEPTIC AGENT; PHENCYCLIDINE;

ARTICLE; AUTOPSY; BRAIN MAPPING; BRAIN METABOLISM; BRAIN MITOCHONDRION; ENERGY METABOLISM; ENZYME ACTIVITY; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RESPIRATORY CHAIN; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031849772     PISSN: 09226028     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. No authors listed, Additional support for schizophrenia linkage on chro-mosomes 6 and 8: a multicenter study. Schizophrenia Linkage Collaborative Group for chromosomes 3, 6 and 8., Am. J. Med. Genet., 67 (1996), 580-594.
2. Akiyama, K., Kanzaki, A., Tsuchida, K. and Ujike, H., Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia. Schiz. Res. 12 (1994), 251-257.
3. Alexander, G.E., and Crutcher, M.D., Functional architecture of basal ganglia circuits: neural substrates of parallel processing, Trends Neurosci., 13 (1990), 266-271.
4. Antonarakis, S.E., Blouin, J.L., Pulver, A.E., Wolyniec, P., Lasseter, V.K., Nestadt, G., Kasch, L., Babb, R., Kazazian, H.H., and Dombroski, B., Schizophrenia susceptibility and chromosome 6p24-22, Nat. Genet., 11 (1995), 235-236.
5. Arinami, T., Gao, M., Hamaguchi, H., and Toru, M., A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet., 6 (1997), 577-582.
6. Arolt, V., Lencer, R., Nolte, A., Muller-Myhsok, B., Purmann, S., Schurmann, M., Leutelt, J., Pinnow, M., and Schwinger, E., Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease, Am. J. Med. Genet., 67 (1996), 564-579.
7. Bagchi, S.P., Effects of phencyclidine on synaptosomal dopamine continuously appearing from phenylalanine: sensitivity to reserpine, Neuropharmacol., 20 (1981), 845-851.
8. Beal, M.F., Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?, Ann. Neurol., 31 (1992), 119-130.
9. Benes, F.M., Todtenkopf, M.S., and Taylor, J.B., Differential distribution of tyrosine hydroxylase fibers on small and large neurons in layer II of anterior cingulate cortex of schizophrenic brain, Synapse 25 (1997), 80-92.
10. Breier, A., Su, T.P., Saunders, R., Carson, R.E., Kolachana, B.S., de Bartolomeis, A., Weinberger, D.R., Weisenfeld, N., Malhotra, A.K., Eckelman, W.C., and Pickar, D., Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method, Proc. Natl. Acad. Scei. U. S. A., 94 (1997), 2569-2574.
11. Buchsbaum, M.S., Haier, R.J., Potkin, S.G., Nuechterlein, K., Bracha, H.S., Katz, M., Lohr, J., Wu, J., Lottenberg, S., Jerabek, P.A., Trenary, M., Tafalla, R., Reynolds, C., and Bunney, W.E., Fontostriatal disorder of cerbral metabolism in never-medicated schizophrenics. Arch. Gen. Psychiat. 49 (1992), 935-942.
12. Buchsbaum, M.S., Ingvar, D.H., Kessler, R., Waters, R.N., Cappelletti, J., van Kammen, D.P., King, A.C., Johnson J.L., Manning, R.G., Flynn, R.W., Mann, L.S., Bunney, W.E. Jr., and Sokoloff, L., Cerebral glucography with positron tomography. Use in normal subjects and in patients with schizophrenia, Arch. Gen. Psychiatry., 39 (1982), 251-259.
13. Carlsson, M., and Carlsson, A., Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease, Trends Neurosci., 13 (1990), 272-276.
14. Carlsson, A., Hansson, L.O., Waters, N., and Carlsson, M.L., Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications, Life. Sci., 61 (1997), 75-94.
15. Cavelier, L., Jazin, E.E., Eriksson, I., Prince, J., Bave, U., Oreland, L., and Gyllensten, U. Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics, Genomics, 29 (1995), 217-224.
16. Dean, B., Hayes, W., Decreased frontal cortical serotonin2A receptors in schizophrenia, Schizophr. Res., 21 (1996), 133-139.
17. Eastwood, S.L., and Harrison, P.J., Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography, Neuroscience, 69 (1995), 339-343.
18. Eastwood, S..L, McDonald, B., Burnet, P.W., Beckwith, J.P., Kerwin, R.W., and Harrison, P.J., Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia, Brain Res. Mol. Brain Res., 29 (1995), 211-223.
19. Ellinwood, E.H. and Kilbey, M.M., Chronic stimulant intoxication models in schizophrenia. In: Animal models in psychiatry and neurology (Hanin, I., Usdin, E. eds), New York, Pergamon Press, 1977, pp 61-74.
20. Ellison, G., Eison, M.S., Huberman, H.S. and Daniel, F., Long-term changes in dopaminergic innervation of caudate nucelus after continuous amphetamine administration. Science 201 (1978), 276-278.
21. Fitzgerald, L.W., Deutch, A.Y., Gasic, G., Heinemann, S.F., and Nestler, E.J., Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs, J. Neurosci., 3 Pt 2 (1995), 2453-2461.
22. Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., Rosenthal, J., Waldo, M.C., Reimherr, F., Wender, P., Yaw, J., Young, D.A., Breese, C.R., Adams, C., Patterson, D., Adler, L.E., Kruglyak, L., Leonard, S., and Byerley, W., Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus, Proc. Natl. Acad. Sci. U. S. A., 94 (1997), 587-592.
23. Freeman, A.S., and Bunney, B.S., The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity, Eur. J. Pharmacol. 104 (1984), 287-293.
24. Gao, X-M., Shirakawa, O., Du, F., and Tamminga, C.A., Delayed regional metabolic actions of phencyclidine, Eur. J. Pharmacol., 241 (1993), 7-15.
25. Gill, M., Vallada, H., Collier, D., Sham, P., Holmans, P., Murray, R., McGuffin, P., Nanko, S., Owen, M., Antonarakis, S., Housman, D., Kazazian, H., Nestadt, G., Pulver, A.E., Straub, R.E., MacLean, C.J., Walsh, D., Kendler, K.S., DeLisi, L., Polymeropoulos, M., Coon, H., Byerley, W., Lofthouse, R., Gershon, E., and Read, C.M., A combined analysis of D22S278 marker alleles in affected sib-pairs: support for a susceptibility locus for schizophrenia at chromosome 22q12. Schizophrenia Collaborative Linkage Group (chromosome 22), Am. J. Med. Genet.., 67 (1996), 40-45.
26. Grace, A.A., Bunney, B.S., Moore, H., and Todd, C.L., Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs, Trends. Neurosci., 20 (1997), 31-37.
27. Harrison, P.J., Schizophrenia: a disorder of neurodevelopment?, Curr. Opin. Neurobiol., 7 (1997), 285-289.
28. Harrison, P.J., McLaughlin, D., and Kerwin, R.W., Decreased hippocampal expression of a glutamate receptor gene in schizophrenia, Lancet , 337 (1991), 450-452.
29. Hertel, P., Mathe, J.M., Nomikos, G.G., Lurlo, M., Mathe, A.A., and Svensson, T.H., Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefcontal cortex of the rat, Behav. Brain Res., 72 (1995), 103-14.
30. Hevner, R.F., Duff, R.S., and Wong-Riley, M.T.T., Coordination of ATP production and consumption in brain: parallel regulation of cytochrome oxidase and Na+,K-t-ATPase, Neurosci. Lett., 138 (1992), 188-192.
31. Holcomb, H.H., Cascella, N.G., Thaker, G.K., Medoff, D.R., Dannals, R.F., and Tamminga, C.A., Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol, Am. J. Psychiat., 153 (1996): 41-49.
32. Ingvar, D.H., and Franzen, G., Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia, Acta. Psychiatr. Scand., 50 (1974), 425-462.
33. Javitt, D.C., and Zukin, S.R., Recent advances in the phencyclidine model of schizophrenia, Am. J. Psychiatry, 148 (1991), 1301-1308.
34. Jentsch, J.D., Elsworth, J.D., Redmond, D.E., and Roth, R.H., Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966, J. Neurosci., 17 (1997), 1769-1775.
35. Jentsch, J.D., Redmond, D.E. Jr., Elsworth, J.D., Taylor, J.R., Youngren, K.D., and Roth, R.H., Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science, 277 (1997), 953-955.
36. Johnstone, E.C., Crow, T.J., Frith, C.D., Carney, M.W., and Price, J.S., Mechanism of the antipsychotic effect in the treatment of acute schizophrenia, Lancet, 1 (1978):848-851
37. Kerwin, R.W., Patel, S., Meldrum, B.S., Czudek, C., and Reynolds, G.P., Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia, Lancet, 1 (1988), 583-584.
38. Kim, J.S., Kornhuber, H.H., Schmid-Burgk, W., and Holzmuller, B., Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia, Neurosci. Lett., 20 (1980), 379-382.
39. Kirov, G., and Murray, R., The molecular genetics of schizophrenia: progress so far, Mol. Med.Today, March (1997), 124-130.
40. Laruelle, M., Abi-Dargham, A., van Dyck, C.H., Gil, R., D'Souza, C.D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S.S., Baldwin, R.M., Seibyl, J.P., Krystal, J.H., Charney, D.S., and Innis, R.B., Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects, Proc. Natl. Acad. Sci. U. S. A., 93 (1996), 9235-9240.
41. Lidow, M.S., Elsworth, J.D., and Goldman-Rakic, P.S., Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs, J. Pharmacol. Exp. Ther., 281 (1997), 597-603.
42. Lidow, M.S., and Goldman-Rakic, P.S., A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc. Natl. Acad. Sci. U. S. A., 91 (1994), 4353-4356.
43. Malhotra, A.K., Pinals, D.A., Adler, C.M., Elman, I., Clifton, A., Pickar, D., and Breier, A., Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics, Neuropsychopharmacology, 17 (1997), 141-150.
44. McCulloch, J., Savaki, H.E., and Sokoloff. L., Distribution of effects of haloperidol on energy metabolism in the rat brain, Brain. Res. 243 (1982), 81-90.
45. McGuffin, P., Asherson, P., Owen, M., and Farmer, A., The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia?, Br. J. Psychiatry 164 (1994), 593-599.
46. Meibach, R.C., Glick, S.D., Cox, R., and Maayani, S., Localisation of phencyclidine-induced changes in brain energy metabolism, Nature, 282 (1979), 625-628.
47. Meloni, R., Laurent, C., Campion, D., Ben Hadjali, B., Thibaut, F., Dollfus, S., Petit, M., Samolyk, D., Martinez, M., and Poirier, M.F., A rare allele of a microsatellite located in the tyrosine hydroxylase gene found in schizophrenic patients, C. R. Acad. Sci. III, 318 (1995), 803-809.
48. Mowry, B.J., Nancarrow, D.J., Lennon, D.P., Sandkuijl, L.A., Crowe, R.R., Silverman, J.M., Mohs, R.C., Siever, L.J., Endicott, J., and Sharpe, L., Schizophrenia susceptibility and chromosome 6p24-22, Nat. Genet., 11 (1995), 233-234.
49. Mrzljak, L., Bergson, C., Pappy, M., Huff, R., Levenson, R., and Goldman-Rakic, P.S., Localization of dopamine D4 receptors in GABAergic neurons of the primate brain, Nature, 381 (1996), 245-248.
50. Murray, A.M., Hyde, T.M., Knable, M.B., Herman, M.M., Bigelow, L.B., Carter, J.M., Weinberger, D.R., and Kleinman, J.E., Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia, J. Neurosci. 3 Pt 2 (1995), 2186-2191.
51. Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., Iyo, M., Tateno, Y., and Toru, M., Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET, Nature, 385 (1997), 634-636.
52. Parent, A., Extrinsic connections of the basal ganglia, Trends Neurosci., 13 (1990), 254-258.
53. Pizzoloto, G., Soncrant, T., and Rapoport, S.I., Haloperidol and cerebral metabolism in the conscious rat: relation to pharmacokinetics, J. Neurochem. 43 (1984), 724-732.
54. Pontieri, F.E., Crane, A.M., Seiden, L.S., Kleven, M.S., and Porrino, L.J., Metabolic mapping of the effects of intravenous methamphetamine administration in freely moving rats. Psychopharmacol., 102 (1990), 175-182.
55. Prince, J., Yassin, M.S., and Oreland, L. (1997a) Neuroleptic-induced mitochondrial enzyme alterations in the rat brain, J. Pharm. Exp. Ther. 280 (1997), 261-267.
56. Prince, J., Yassin, M.S., and Oreland, L., A histochemical demonstration of altered cytochrome oxidase acitivty in the rat brain by neuroleptics. Eur. Neuropsychopharmacol., in press.
57. Prince, J. A., Yassin, M., and Oreland, L., Normalization of cytochrome-c oxidase activity in the rat brain by neuroleptics after chronic treatment with PCP or methamphetamine, Neuropharmacalogy, in press.
58. Pulver, A.E., Karayiorgou, M., Wolyniec, P.S., Lasseter, V.K., Kasch, L., Nestadt, G., Antonarakis, S., Housman, D., Kazazian, H.H., and Meyers, D., Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: Part 1, Am. J. Med. Genet., 54 (1994), 36-43.
59. Randrup, A., and Munkvad, I., Role of catecholamines in the amphetamine excitatory response. Nature, 211 (1966), 540.
60. Sato, M., Chen, C.C., Akiyama, K., and Otsuki, S., Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis, Biol. Psychiatry, 18 (1983), 429-440.
61. Sato, M., A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis, Ann. N. Y. Acad. Sci., 654 (1992), 160-170.
62. Sedvall, G., and Farde, L., Dopamine receptors in schizophrenia, Lancet, 347 (1996), 264.
63. Seeman, P., Guan, H.C., and Van Tol, H.H., Dopamine D4 receptors elevated in schizophrenia, Nature , 365 (1993), 441-445.
64. Seeman, P., Lee, T., Chau-Wong, M., and Wong, K., Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature, 261 (1976), 717-719.
65. Seeman, P., and Van Tol, H.H., Dopamine receptor pharmacology,Trends. Pharmacol. Sci., 15 (1994), 264-270.
66. Seeman, P., and Van Tol, H.H., Dopamine D4-like receptor elevation in schizophrenia: cloned D2 and D4 receptors cannot be discriminated by raclopride competition against [3H]nemonapride, J. Neurochem., 64 (1995), 1413-1415.
67. Selemon, L.D., Rajkowska, G., and Goldman-Rakic, P.S., Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17, Arch. Gen. Psychiatry, 52 (1995), 805-818.
68. Silbersweig, D., and Stern, E., Functional neuroimaging of hallucinations in schizophrenia: toward an integration of bottom-up and top-down approaches, Mol. Psychiatry, 1 (1996), 367-375.
69. Smiley, J..F, Levey, A.I., Ciliax, B.J., and Goldman-Rakic, P.S., D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines, Proc. Natl. Acad. Sci. U. S. A., 91 (1994), 5720-5724.
70. Snyder, S.H., Catecholamines in the brain as mediators of amphetamine psychosis, Arch. Gen. Psychiatry, 27 (1972), 169-179.
71. Sokoloff, L., Relation between physiological function and energy metabolism in the central nervous system, Neurochem, 29 (1977), 13-26.
72. Sumiyoshi, T., Stockmeier, C.A., Overholser, J.C., Dilley, G.E., and Meltzer, H.Y., Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia, Brain Res., 708 (1996), 209-214.
73. Tamminga, C.A., Thaker, G.K., Buchanen, R., Kirkpatrick, B., Alphs, L.D., Chase, T.N., and Carpenter, W.T., Limbic abnormailities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiat. 49 (1992), 522-530.
74. Tarazi, F.I., Shirakawa, O., and Tamminga, C.A., Low dose raclopride spares the extrapyramidal system in the rat brain from metabolic effects, Eur. J. Pharmacol. 232 (1993), 71-77.
75. Vollenweider, F.X., Leenders, K.L., Oye, I., Hell, D., and Angst, J., Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET), Eur. Neuropsychopharmacol., 7 (1997), 25-38.
76. Wagner, G.C., Ricaurte, G.A., Seiden, L.S., Schuster, C.R., Miller, R.J., and Westley, J., Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine, Brain. Res., 181 (1980), 151-160.
77. Whatley, S.A., Curti, D., and Marchbanks, R.M., Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem. Res., 21 (1996), 995-1004.
78. White, I.M., Flory, G.S., Hooper, K.C., Speciale, J., Banks, D.A., and Rebec, G.V., Phencyclidine-induced increases in striatal neuron firing in behaving rats: reversal by haloperidol and clozapine, J. Neural. Trans. 102 (1995), 99-112.
79. Williams, J., Spurlock, G., McGuffin, P., Mallet, J., Nothen, M.M., Gill, M., Aschauer, H., Nylander, P.O., Macciardi, F., and Owen, M.J., Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group, Lancet, 347 (1996), 1294-1296.
80. Wilson, J.M., Kalasinsky, K.S., Levey, A.I., Bergeron, C., Reiber, G., Anthony, R.M., Schmunk, G.A., Shannak, K., Haycock, J.W., and Kish, S.J., Striatal dopamine nerve terminal markers in human, chronic methamphetamine users, Nat. Med., 2 (1996), 699-703.
81. Wong-Riley, M., Changes in the visual system of monocularly sutured or enucleated cats demonstrable with cytochrome oxidase histochemistry, Brain Res. 171 (1979), 11-28.
82. Wong-Riley, M., Cytochrome Oxidase: an endogenous metabolic marker for neuronal activity, TINS 12 (1989), 94-101.
83. Wong-Riley, M., and Carrol, E.W., Effect of impulse blockage on cytochrome oxidase activity in monkey visual system, Nature, 307 (1984), 262-264.